The store will not work correctly when cookies are disabled.
We use cookies for optimal website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.
Allow cookies Deny
BI-78D3; 4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-((5-nitrothiazol-2-yl)thio)-1H-1,2,4-triazol-5(4H)-one; CAS No.: 883065-90-5; BI-78D3. PROPERTIES: BI-78D3 is a crystalline solid with the molecular formula C23H22F3N5O3S. It exhibits moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at room temperature but recommended storage involves protection from light and moisture in a sealed container. Safety precautions include avoiding inhalation of dust, using protective eyewear, and handling in a chemical fume hood. With a molecular weight of approximately 515.51 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms and sulfur-containing groups that enhance binding affinity and metabolic resistance. Its logP value around 3.0 indicates a balance between solubility and membrane permeability. APPLICATIONS: BI-78D3 functions as a potent and selective inhibitor of the Bruton's tyrosine kinase (BTK), investigated for the treatment of B-cell malignancies and autoimmune diseases. In preclinical research, it is used to study BTK's role in B-cell receptor signaling and to develop novel therapeutic approaches. The compound is employed in combination studies with other targeted therapies to enhance antitumor efficacy. Additionally, it serves as a research tool in immunology to investigate B-cell biology and in drug discovery to explore structure-activity relationships of BTK inhibitors. According to "Bruton's Tyrosine Kinase as a Therapeutic Target in Oncology and Immunology," BI-78D3 provides a valuable platform for targeting BTK-mediated signaling pathways.